Favezelimab/pembrolizumab explained

Type:	combo
Component1:	Favezelimab
Class1:	Anti–LAG-3 monoclonal antibody
Component2:	Pembrolizumab
Class2:	Anti-PD-1 monoclonal antibody
Legal Status:	Investigational

Favezelimab/pembrolizumab is a fixed-dose combination of two monoclonal antibodies developed by Merck to treat various cancers.^{[1] [2] [3] [4] [5]}

Notes and References

1. Timmerman . John . Lavie . David . Johnson . Nathalie A. . Avigdor . Abraham . Borchmann . Peter . Andreadis . Charalambos . Bazargan . Ali . Gregory . Gareth P. . Keane . Colm . Tsoran-Rosenthal . Inna . Vucinic . Vladan . Zinzani . Pier Luigi . West . Rachel Marceau . Pillai . Pallavi . Nahar . Akash . Herrera . Alex F. . Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment . Blood . 15 November 2022 . 140 . Supplement 1 . 768–770 . 10.1182/blood-2022-166670. 260785891 . free .
2. Timmerman . John . Lavie . David . Johnson . Nathalie A. . Avigdor . Abraham . Borchmann . Peter . Andreadis . Charalambos . Bazargan . Ali . Gregory . Gareth . Keane . Colm . Inna . Tzoran . Vucinic . Vladan . Zinzani . Pier Luigi . Zhang . Hong . Pillai . Pallavi . Marinello . Patricia . Herrera . Alex Francisco . Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study. . Journal of Clinical Oncology . 1 June 2022 . 40 . 16_suppl . 7545 . 10.1200/JCO.2022.40.16_suppl.7545. 249445835 .
3. Garralda . E. . Sukari . A. . Lakhani . N.J. . Patnaik . A. . Lou . Y. . Im . S.-A. . Golan . T. . Geva . R. . Wermke . M. . de Miguel . M. . Palcza . J. . Jha . S. . Chaney . M. . Abraham . A.K. . Healy . J. . Falchook . G.S. . A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer . ESMO Open . December 2022 . 7 . 6 . 100639 . 10.1016/j.esmoop.2022.100639. 36493599 . 9832734 .
4. Rha . Sun Young . Miller . Wilson H. . de Miguel . María José . Im . Seock-Ah . Lugowska . Iwona . Wermke . Martin . Kotani . Daisuke . Bauer . Todd Michael . Takashima . Atsuo . Palcza . John . Chaney . Marya F. . Dobrenkov . Konstantin . Garralda . Elena . Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer. . Journal of Clinical Oncology . 1 February 2023 . 41 . 4_suppl . 394 . 10.1200/JCO.2023.41.4_suppl.394. 256265890 .
5. Garralda . Elena . Sukari . Ammar . Lakhani . Nehal J. . Patnaik . Amita . Lou . Yanyan . Im . Seock-Ah . Golan . Talia . Geva . Ravit . Wermke . Martin . De Miguel . Maria . Palcza . John . Jha . Sujata . Chaney . Marya F. . Healy . Jane Anne . Falchook . Gerald Steven . A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. . Journal of Clinical Oncology . 20 May 2021 . 39 . 15_suppl . 3584 . 10.1200/JCO.2021.39.15_suppl.3584. 236349131 .